20/20 Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

20/20 Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$537K	Buy	3,969 +544	+16%	+$71.5K	0.14%	98
2021 Q1	$465K	Buy	3,425 +235	+7%	+$35.2K	0.13%	104
2020 Q4	$521K	Buy	+3,190	New	+$409K	0.15%	102

Other funds holding XBI

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

20/20 Capital Management's XBI Position: Q2 2021 in Review

20/20 Capital Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 16% in Q2 2021, buying an estimated $71.5K and bringing the position to 3,969 shares worth $537K. The position accounts for 0.14% of the portfolio, ranked #98.

20/20 Capital Management first reported a position in XBI in Q4 2020 and has held it in 3 quarters since. 663 funds tracked by Wall St. Rank hold XBI as of Q2 2021.

20/20 Capital Management held 3,969 shares of State Street SPDR S&P Biotech ETF worth $537K as of Q2 2021.
20/20 Capital Management bought 544 State Street SPDR S&P Biotech ETF shares in Q2 2021, an estimated $71.5K.
State Street SPDR S&P Biotech ETF made up 0.14% of 20/20 Capital Management's portfolio in Q2 2021, its #98 holding.
20/20 Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and has held it in 3 quarters since.
663 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2021.

Based on 20/20 Capital Management's 13F filing for Q2 2021, filed 12 Jul 2021.